I have written previously (opednews.com/articles/Marketing-Serotonin-Defici-by-Dr-Stuart-Jeanne-B-100713-513.html) about the ingenious — and deadly — strategy by pharmaceutical companies of inventing fictitious illnesses to market highly profitable drugs that allegedly “treat” them. the technical terms for this are “medicalizing” or “disease mongering.” Dr Marcia Angell, in her 2004 the Truth about the Drug Companies: how They Deceive Us and What To do about it, also talks about “generalized anxiety disorder,” “erectile dysfunction,” “premenstrual dysphoric disorder,” and “gastro-esophogeal reflux disorder (heartburn)” as examples of common complaints that drug companies have reinvented as chronic illnesses requiring lifelong treatment (see cmaj.ca/cgi/content/full/171/12/1451).

Estrogen Deficiency Syndrome

the marketing of so-called “estrogen deficiency syndrome,” which is known as “menopause” in English-speaking countries (other cultures have no word for it) and “hormone replacement therapy (HRT)” has been far more lethal, in view of 30 years of research linking it to reproductive cancers. the number of premature deaths linked to HRT is estimated in the millions. In this case the culprit is a single company, Wyeth, which manufactures Premarin (conjugated estrogens extracted from pregnant mare urine) and Prempro, a combination of estrogen and a second female hormone progesterone.

Although the medical community (and Wyeth) have been aware of links between estrogen replacement and breast, uterine and ovarian cancer since the 1970s, the research was effectively concealed from public view — until the frightening results of the Women’s Health Initiative (WHI) study hit the front page in 2002. Between 1993 and 1995, the National Institutes of Health enrolled 161,809 women in the double blind WHI study. In 2002 the NHI shut down the study, originally scheduled to finish in 2005, when it became clear that the women taking HRT were experiencing a 26% increase in breast cancer (with the risk doubling after five years), a 41% increase in strokes and a 29% increase in heart disease (see theepochtimes.com/n2/content/view/9804/).

Estrogen, a hormone regulating the development and function of the female reproductive system, was first discovered in 1925. In the 1930s, the drug company Wyeth developed a process (viewed as barbaric by animal rights activists) to extract conjugated estrogens from the urine of pregnant mares. They patented their product as the drug Premarin (PREgnantMAresurINe), which first appeared on the market in 1942.

From the beginning Wyeth marketed Premarin, not for temporary relief of menopausal symptoms, but as a lifelong treatment to help all women maintain “healthy” estrogen levels in later life. obviously this is nonsense, as a “healthy” or natural estrogen level in a post-menopausal woman is virtually zero.

1975: the First Study Linking Premarin with Cancer

the first study linking Premarin with increased uterine cancer appeared in 1975. it was replicated by other researchers in 1977 and 1979. These results were entirely consistent with the discovery of estrogen receptors in the early seventies and the finding that stimulating these receptors caused tumor growth in tissue culture and laboratory animals.

Wyeth responded to these worrisome studies by promoting a small 1980 study that taking progesterone, a second female hormone, reduced the risk of uterine cancer with estrogen replacement. unfortunately most doctors fell for Wyeth’s slick PR campaign (the free pens, watches, clocks, lunches, trips to overseas conferences may have had something to do with it). They somehow overlooked the failure of 1980 study to look at the cancer rates in women who took no hormone replacement or to study the possible role of this combination in inducing other hormone sensitive cancers, like breast and ovarian cancer. In fact, their success in selling doctors on the combination, led Wyeth to launch Prempro in 1995, which combined Premarin with progesterone.

the earliest studies linking Premarin with breast cancer appeared in early 1980. as Nik Ismail points out in “Hormone Replacement Therapy and Gynaecological Cancers,” between 1975 and 1995, there were at least fifty studies linking estrogen replacement (also known as HRT) with breast and uterine cancer. Some were cross cultural studies revealing American women had more than ten times the incidence of breast cancer than Asian women, who don’t take estrogen replacement (see gfmer.ch/Books/bookmp/113.htm).

the Multibillion Dollar Wyeth Cover-up

Wyeth responded to the breast cancer studies with a new PR blitz. In addition to flooding doctors’ offices with literature claiming studies linking Premarin to cancer were “contradictory,” they promoted numerous company-funded studies allegedly showing that estrogen replacement prevents osteoporosis and hip fractures, dementia and heart disease. the spin Wyeth gave doctors was that the effect of reducing cardiovascular disease (heart disease and strokes) — the most common cause of death in Americans — outweighed the somewhat lower risk of developing breast cancer. Ultimately the claim that Premarin and Prempro reduce elderly women;s risk of cardiovascular disease proved to be false. In fact this was one of the main reasons the WHI study was stopped: the women in the Premarin/Prempro arm of the study were developing significantly more heart attacks, strokes and dementia.

the role of estrogen replacement in reducing osteoporosis was supported by the WHI and other studies. however thus far, no studies have controlled for long term fluoride ingestion or epidemic Vitamin D deficiency in elderly Americans — which both have a documented role in high US rates of osteoporosis and hip fracture.

the marketing blitz aimed at doctors was accompanied by an even more powerful PR campaign in Harper’s Bazaar, the Ladies Home Journal and other women’s magazines, appealing to American women’s (largely manufactured) terror of aging by emphasizing the value of estrogen replacement in preserving sexual attractiveness by preventing the skin changes and vaginal drying associated with aging.

Premarin Ads by Otherwise

Menopause: made in the USA

 1  |  2

WASHINGTON (Reuters) – Prescriptions for hormone replacement therapy have fallen more than 50 percent in the United States since 2001, but doctors are still inexplicably giving women high-dose pills linked to strokes and cancer, researchers reported on Thursday.

The U.S. Food and Drug Administration and other groups do not say women should avoid hormone replacement therapy, or HRT, but they recommend taking the lowest possible dose for the shortest period of time.

"We're disappointed," Dr. Randall Stafford of Stanford University in California, who led the study, said in a statement.

"Yes, there was an increase in the use of low-dose preparations, but it was not sizeable."

Hormone replacement therapy is used by women who are going through or who have gone through menopause to relieve symptoms that range from hot flashes, low energy, sleeplessness and vaginal dryness to bone loss.

Doctors once believed HRT also prevented heart disease and cancer, but the Women's Health Initiative found in 2002 that women who took estrogen plus progesterone pills for five years had higher rates of ovarian cancer, breast cancer, strokes and other health problems.

Sales of U.S. market leader Wyeth's combined estrogen plus progesterone pill Prempro have fallen by about 50 percent since 2001 to around $1 billion a year. Wyeth is now owned by Pfizer.

Many makers of HRT have reformulated their products, offering much lower doses of hormone, often as patches, creams or vaginal delivery products.

Stafford and colleagues looked at data from 340,820 patient visits to hospitals, clinics and doctor's offices, as well as information from telephone calls.

They found that use of HRT fell by 52 percent from 2001 to 2009, from 17.5 million users to 8.3 million users. but the women using HRT were often still getting relatively high doses of hormones in the pills.

"Despite reduced use, standard-dose oral (HRT) remains the dominant formulation, yet lower dose transdermal and vaginal preparations may yield less harm," they wrote in Menopause: the Journal of the North American Menopause Society.

"We thought that over time there might be greater tailoring of therapy based on characteristics of the individual woman," Stafford said. "the bottom line is that over time we didn't see the level of refinement in clinical practice that we expected."

Many experts believe that lower-dose formulations and skin patches may be a safer way to deliver HRT. the patches, in particular, may reduce the amount of hormones reaching vulnerable organs.

In 2001, more than 16 million women took some form of HRT pill, but by 2009, 6 million did, the survey found.

Lower-dose product use increased modestly, from 700,000 in 2001 to 1.3 million in 2009, they found.

In October, researchers reported that women who took hormone replacement pills had more advanced breast cancers and were more likely to die from them than women who took a dummy pill. [ID:nN19153576] In June, a different team found that women using low-dose patches were less likely to have strokes than women taking pills [ID:nN03253698].

(Reporting by Maggie Fox)